Laurus Labs Stock Screener | Share Price & Fundamental Analysis
LAURUSLABS
Pharmaceuticals
Screen Laurus Labs share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹1128.50
▲
12.60 (1.13%)
Share Price BSE
₹1128.70
▲
12.90 (1.16%)
Market Cap
₹60,242.60 Cr.
P/E Ratio (TTM)
87.30
P/B Ratio
12.39
EPS (TTM)
₹6.65
Dividend Yield
0.11%
Debt to Equity
0.62
52W High
₹1128.50
52W Low
₹510.75
Operating Margin
24.00%
Profit Margin
11.61%
Revenue (TTM)
₹1,680.00
EBITDA
₹430.00
Net Income
₹195.00
Total Assets
₹9,336.00
Total Equity
₹4,603.00
Laurus Labs Share Price History - Stock Screener Chart
Screen LAURUSLABS historical share price movements with interactive charts. Analyze price trends and patterns.
Laurus Labs Company Profile - Fundamental Screener
Screen Laurus Labs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for LAURUSLABS shares.
Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company based in India. It operates in four business lines: Generics - APIs, Generics - FDFs, Synthesis, and Ingredients. The company specializes in active pharmaceutical ingredients (APIs) for anti-retrovirals, Hepatitis C, and Oncology, among other therapeutic areas. Laurus Labs...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Ravindranath Kancherla
ISIN
INE947Q01028
Website
https://www.lauruslabs.com
Laurus Labs Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen LAURUSLABS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 9,336 | 8,387 | 7,660 | 6,968 | 5,751 | 3,750 | 3,331 | 3,017 | 2,653 | 2,224 |
| Current Assets | 4,332 | 3,835 | 3,462 | 3,345 | 3,075 | 1,812 | 1,463 | 1,248 | 1,140 | 1,003 |
| Fixed Assets | 4,123 | 3,890 | 3,409 | 2,653 | 2,171 | 1,726 | 1,629 | 1,481 | 1,230 | 1,021 |
| Liabilities | ||||||||||
| Total Liabilities | 9,336 | 8,387 | 7,660 | 6,968 | 5,751 | 3,750 | 3,331 | 3,017 | 2,653 | 2,224 |
| Current Liabilities | 1,193 | 1,159 | 1,180 | 928 | 693 | 288 | 349 | 227 | 202 | 483 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 4,603 | 4,116 | 4,049 | 3,359 | 2,601 | 1,770 | 1,558 | 1,483 | 1,330 | 857 |
| Share Capital | 108 | 108 | 108 | 108 | 107 | 107 | 106 | 106 | 106 | 82 |
| Reserves & Surplus | 4,365 | 4,003 | 3,930 | 3,244 | 2,490 | 1,658 | 1,447 | 1,371 | 1,225 | 774 |
Screen LAURUSLABS income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun | 2022-Mar |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,680 | 1,580 | 1,779 | 1,425 | 1,228 | 1,197 | 1,458 | 1,197 | 1,226 | 1,185 | 1,383 | 1,546 | 1,577 | 1,541 | 1,426 |
| Expenses | 1,250 | 1,187 | 1,300 | 1,130 | 1,045 | 1,024 | 1,198 | 1,014 | 1,037 | 1,015 | 1,095 | 1,141 | 1,127 | 1,085 | 1,028 |
| EBITDA | 430 | 393 | 479 | 295 | 183 | 174 | 260 | 184 | 190 | 170 | 287 | 405 | 450 | 456 | 398 |
| Operating Profit % | 24.00% | 24.00% | 24.00% | 20.00% | 15.00% | 14.00% | 17.00% | 15.00% | 15.00% | 14.00% | 21.00% | 26.00% | 28.00% | 30.00% | 28.00% |
| Depreciation | 121 | 117 | 110 | 106 | 108 | 106 | 102 | 98 | 93 | 91 | 87 | 84 | 82 | 71 | 66 |
| Interest | 40 | 52 | 56 | 58 | 53 | 49 | 51 | 51 | 42 | 39 | 53 | 43 | 40 | 29 | 31 |
| Profit Before Tax | 270 | 224 | 312 | 131 | 23 | 19 | 107 | 35 | 54 | 41 | 147 | 278 | 328 | 356 | 302 |
| Tax | 75 | 63 | 80 | 38 | 3 | 6 | 32 | 11 | 17 | 14 | 42 | 75 | 95 | 104 | 70 |
| Net Profit | 195 | 162 | 233 | 93 | 20 | 13 | 75 | 23 | 37 | 27 | 105 | 203 | 233 | 252 | 232 |
| EPS | 3.61 | 3.02 | 4.34 | 1.71 | 0.37 | 0.23 | 1.40 | 0.43 | 0.69 | 0.46 | 1.90 | 3.78 | 4.33 | 4.68 | 4.29 |
Laurus Labs Cash Flow Screener - Liquidity Fundamentals
Screen LAURUSLABS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 602 | 666 | 994 | 911 | 733 | 347 | 298 | 343 | 332 | 182 |
| Investing Activities | -680 | -822 | -997 | -915 | -941 | -221 | -253 | -384 | -289 | -312 |
| Financing Activities | 39 | 250 | -27 | 30 | 255 | -128 | -45 | 42 | -54 | 103 |
| Net Cash Flow | -39 | 93 | -30 | 27 | 47 | -1 | 0 | 1 | -10 | -27 |
Screen LAURUSLABS shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 27.59% | 27.59% | 27.62% | 27.19% | 27.18% | 27.18% | 27.62% | 27.20% |
| FII Holding | 26.16% | 25.70% | 25.52% | 25.97% | 25.67% | 26.08% | 25.56% | 0.02% |
| DII Holding | 11.73% | 11.94% | 11.77% | 11.77% | 13.56% | 13.05% | 12.74% | 9.74% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.33% | 23.12% | 23.65% | 23.95% | 22.68% | 22.67% | 22.72% | 28.49% |
| Other Holding | 11.18% | 11.65% | 11.44% | 11.12% | 10.91% | 11.03% | 11.36% | 34.55% |
| Shareholder Count | 283,678 | 280,223 | 292,905 | 356,830 | 324,059 | 309,063 | 292,214 | 418,615 |
Laurus Labs Dividend Screener - Share Yield Analysis
Screen LAURUSLABS dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.20 | 0.11% |
| 2024-March | ₹0.80 | 0.13% |
| 2023-March | ₹2.00 | 0.51% |
| 2022-March | ₹2.00 | 0.67% |
| 2021-March | ₹2.00 | 0.34% |
| 2020-March | ₹2.50 | 0.69% |
| 2019-March | ₹1.50 | 2.31% |
| 2018-March | ₹1.50 | 1.88% |
| 2017-March | ₹1.50 | 1.49% |
Laurus Labs Index Membership - Market Screener Classification
Screen LAURUSLABS by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Laurus Labs Market Events Screener - Corporate Actions
Screen LAURUSLABS market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2025-10-31 | 2025-10-31 | Dividend | ₹ 0.80 /share | 5.03% |
| 2025-10-23 | 2025-10-23 | Quarterly Result Announcement | NA | 7.65% |
| 2025-07-25 | 2025-07-25 | Quarterly Result Announcement | NA | 7.48% |
| 2025-06-26 | 2025-06-26 | Annual General Meeting | NA | 10.52% |
| 2025-05-09 | 2025-05-09 | Dividend | ₹ 0.80 /share | -9.91% |
| 2025-04-24 | 2025-04-24 | Quarterly Result Announcement | NA | 15.28% |
| 2025-01-24 | 2025-01-24 | Quarterly Result Announcement | NA | -4.35% |
| 2024-11-06 | 2024-11-06 | Dividend | ₹ 0.40 /share | 8.88% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -6.44% |
| 2024-07-11 | 2024-07-11 | Annual General Meeting | NA | 8.77% |
| 2024-05-08 | 2024-05-08 | Dividend | ₹ 0.40 /share | -1.14% |
| 2023-11-02 | 2023-11-02 | Dividend | ₹ 0.40 /share | -9.46% |
| 2023-05-10 | 2023-05-10 | Dividend | ₹ 1.20 /share | 11.41% |
| 2022-11-03 | 2022-11-04 | Dividend | ₹ 0.80 /share | -9.21% |
| 2022-05-10 | 2022-05-11 | Dividend | ₹ 1.20 /share | -9.28% |
Laurus Labs Competitors Screener - Peer Comparison
Screen LAURUSLABS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 422,331 | 39.59 | 54,729 | 9.71% | 10,980 | 53.13 |
| Divis Laboratories | 176,338 | 67.97 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 133,239 | 61.20 | 11,539 | 6.99% | 1,911 | 71.28 |
| Cipla | 123,654 | 22.59 | 28,410 | 7.12% | 5,291 | 57.84 |
| Dr Reddys Laboratories | 104,846 | 18.17 | 33,741 | 16.73% | 5,725 | 46.16 |
| Lupin | 98,198 | 21.84 | 22,910 | 13.74% | 3,306 | 63.46 |
| Zydus Life Science | 93,685 | 18.44 | 23,511 | 18.55% | 4,615 | 54.52 |
| Mankind Pharma | 92,501 | 51.05 | 12,744 | 20.90% | 2,007 | 56.13 |
| Aurobindo Pharma | 71,514 | 20.50 | 32,346 | 9.43% | 3,484 | 60.21 |
| Alkem Laboratories | 67,620 | 27.57 | 13,458 | 3.70% | 2,216 | 55.49 |
Laurus Labs Company Announcements - News Screener
Screen LAURUSLABS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-31 | Closure of Trading Window | View |
| 2025-12-23 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | View |
| 2025-12-23 | Announcement under Regulation 30 (LODR)-Updates on Acquisition | View |
| 2025-12-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-12-02 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | View |
| 2025-11-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-11-01 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-28 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-10-24 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-10-23 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-10-23 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-10-23 | Corporate Action-Board approves Dividend | View |
| 2025-10-23 | Board Meeting Outcome for Approval Of Unaudited Financial Statements For The Quarter And Half Year Ended September 30 2025 And Approval For Payment Of Interim Dividend For FY 2025-26 | View |
| 2025-10-23 | Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-09 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-09 | Board Meeting Intimation for Inter-Alia To Consider The Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2025 And The Proposal For Payment Of Interim Dividend For FY 2025-26 | View |
| 2025-10-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-26 | Closure of Trading Window | View |